- Can you have too many relationships with introducers? (part 1)
- How To Integrate Continuous Improvement Into Your Organization’s Culture And Daily Activities
- Identify The Strengths Of Your Services And Where Improvements Can Be Leveraged
- How To Succeed In A Continually Changing And Unstructured Workplace
- 6 tips to get back in touch with an old colleague
- Paving the Last Mile of Big Data Analytics
- Important Considerations For An Organizational Restructuring
- Elevator Speech 2.0 = Elevator Dialogue
- 4 ways to qualify a lead
- Is the Trusted Advisor Still Trusted?
PwC: Michael Swanick Appointed
November 19, 2012
By Rob Starr, Content Manager, Big4.com
A 28-year veteran of PwC, Michael Swanick most recently held the position of PwC’s U.S. Pharmaceutical and Life Sciences Leader and Global Tax Leader for the practice. He will continue to serve in this capacity, while taking on additional global responsibilities for the firm. He was recently appointed as Global Pharmaceutical and Life Sciences Industry leader succeeding Simon Friend. As the global practice leader, Swanick is responsible for the strategy and direction of the firm’s multinational pharmaceutical, medical device and life sciences practice, which is comprised of approximately 4,700 industry dedicated professionals around the world.
Based in Philadelphia, Swanick joined the firm in 1984 and has been a tax partner for nearly 20 years. He has worked on tax consulting and compliance matters for international and domestic pharmaceutical and life science companies, as well as manufacturing and medical device companies. He was the lead author of the firm’s 2009 report, Pharma 2020: Taxing times ahead, which brought a tax perspective to an analysis of the complex forces impacting pharmaceutical and life sciences companies through 2020.
“Mike is uniquely qualified for this role having been at the forefront of this industry for nearly three decades while at PwC,” said David Levy, MD, Global Health Industries practice leader with PwC. “As the global environment for pharmaceutical and life sciences companies becomes increasingly complex with greater demand from regulators, payers, providers and consumers, we remain committed to helping clients navigate challenging market dynamics and working with them to develop new, innovative approaches to enable continued success in the marketplace.”